Docetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follow‐Up

LESSONS LEARNED. Adding docetaxel to the modified FOLFOX7 backbone (DOF) is a feasible three‐drug combination therapy for advanced gastric cancer with high activity, providing evidence that leucovorin is not necessary in this setting. The DOF regimen represents an alternative to the FLOT (5‐FU 2,600...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenberg, Ari Joseph, Rademaker, Alfred, Hochster, Howard S., Ryan, Theresa, Hensing, Thomas, Shankaran, Veena, Baddi, Lisa, Mahalingam, Devalingam, Mulcahy, Mary F., Benson, Al B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693711/
https://www.ncbi.nlm.nih.gov/pubmed/31138725
http://dx.doi.org/10.1634/theoncologist.2019-0330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693711/
https://www.ncbi.nlm.nih.gov/pubmed/31138725
http://dx.doi.org/10.1634/theoncologist.2019-0330

Ejemplares similares